Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | CLPP | Q16740 | 10/20 | 0.87 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.87 |
| ▸ | DRD2 | P14416 | 1/20 | 0.87 |
| ▸ | DRD3 | P35462 | 1/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.87 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30085760 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2HIF1ACLPPGPR132 | |
| Dordaviprone SCHEMBL16227974 | 0.93 | CLPP (1.00) | CYP3A4SMN1; SMN2HIF1ACLPPGPR132 | |
| Dordaviprone SCHEMBL29359574 | 0.93 | CLPP (1.00) | CYP3A4SMN1; SMN2HIF1ACLPPGPR132 | |
| Dordaviprone SCHEMBL29414943 | 0.92 | CLPP (0.98) | CYP3A4SMN1; SMN2HIF1ACLPPGPR132 | |
| Dordaviprone SCHEMBL31548590 | 0.92 | CLPP (0.98) | CYP3A4SMN1; SMN2HIF1ACLPPGPR132 | |
| SCHEMBL22065223 | 0.88 | CYP3A4 (0.79) | CYP3A4SMN1; SMN2HIF1ACLPPGPR132 | |
| SCHEMBL20173633 | 0.87 | CLPP (0.89) | CYP3A4SMN1; SMN2HIF1ACLPPGPR132 | |
| SCHEMBL18427332 | 0.87 | CYP3A4 (0.77) | CYP3A4SMN1; SMN2HIF1ACLPPGPR132 | |
| SCHEMBL18254945 | 0.87 | CLPP (0.85) | CYP3A4SMN1; SMN2HIF1ACLPPGPR132 | |
| SCHEMBL18254991 | 0.87 | CLPP (0.89) | CYP3A4SMN1; SMN2HIF1ACLPPGPR132 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2019-03-28 | — | — | US | claimed |
| US-20180369264-A1 | COMBINATION OF A CARDIAC STEROID AND AN AKT INHIBITOR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISORDERS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-12-27 | — | — | US | claimed |
| EP-3393477-A1 | COMBINATION OF A CARDIAC STEROID AND AN AKT INHIBITOR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISORDERS | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2018-10-31 | — | — | EP | claimed |
| WO-2017109778-A1 | COMBINATION OF A CARDIAC STEROID AND AN AKT INHIBITOR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISORDERS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2017-06-29 | — | — | WO | claimed |
| WO-2017042634-A2 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES AND ANALOGS THEREOF FOR TREATMENT OF NON-SMALL-CELL LUNG CARCINOMA, GLIOBLASTOMA, AND OVARIAN CARCINOMA BY INDUCTION OF DNA DAMAGE AND STALLING OF CELL CYCLE | DEL MAR PHARMACEUTICALS (CA) | 2017-03-16 | — | — | WO | claimed |
| US-12630550-B2 | Pharmacophore for trail induction | THE SCRIPPS RESEARCH INSTITUTE (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4706682-A2 | SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY | The Penn State Research Foundation (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20240415841-A1 | SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY | THE PENN STATE RESEARCH FOUNDATION (US) | 2024-12-19 | — | — | US | disclosed |
| EP-4470617-A2 | PHARMACOPHORE FOR TRAIL INDUCTION | The Scripps Research Institute (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-3662910-B1 | PHARMACOPHORE FOR TRAIL INDUCTION | SCRIPPS RESEARCH INST (US) | 2024-09-18 | — | — | EP | disclosed |
| US-12036223-B2 | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | THE PENN STATE RESEARCH FOUNDATION (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240190877-A1 | PHARMACOPHORE FOR TRAIL INDUCTION | THE SCRIPPS RESEARCH INSTITUTE | 2024-06-13 | — | — | US | disclosed |
| US-20140271540-A1 | 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3H)-one, Salts thereof And Methods of Using The Same in Combination Therapy | ONCOCEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140248264-A1 | SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY | THE PENN STATE RESEARCH FOUNDATION (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140248264-A1 | SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY | THE PENN STATE RESEARCH FOUNDATION (US) | 2014-09-04 | — | — | US | disclosed |
| US-8673923-B2 | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | THE PENN STATE RESEARCH FOUNDATION (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673923-B2 | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | THE PENN STATE RESEARCH FOUNDATION (US) | 2014-03-18 | — | — | US | disclosed |
| WO-2012149546-A2 | SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120276088-A1 | SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120276088-A1 | SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036223-B2 | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | TSG101, TNFSF10, BCL2L10 | CYP3A4 4677/4885SMN1; SMN2 1225/4885HIF1A 3479/4885 |
| US-12630550-B2 | Pharmacophore for trail induction | STAT3, STAT1, STAT4 | CYP3A4 218/4885SMN1; SMN2 3993/4885HIF1A 3416/4885 |
| US-20140248264-A1 | SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY | TSG101, TNFSF10, BCL2L10 | CYP3A4 4677/4885SMN1; SMN2 1225/4885HIF1A 3479/4885 |
| US-20240415841-A1 | SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY | TSG101, TNFSF10, BCL2L10 | CYP3A4 4677/4885SMN1; SMN2 1225/4885HIF1A 3479/4885 |
| US-20120276088-A1 | SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY | TSG101, TNFSF10, BCL2L10 | CYP3A4 4677/4885SMN1; SMN2 1225/4885HIF1A 3479/4885 |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DDOST, DCLRE1A, OGG1 | CYP3A4 3533/4885SMN1; SMN2 2556/4885HIF1A 2435/4885 |
| US-20140271540-A1 | 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3H)-one, Salts thereof And Methods of Using The Same in Combination Therapy | PAICS, TPMT, THPO | CYP3A4 3739/4885SMN1; SMN2 11/4885HIF1A 2621/4885 |
| US-20240190877-A1 | PHARMACOPHORE FOR TRAIL INDUCTION | AIFM1, TNFRSF1A, TNFSF10 | CYP3A4 205/4885SMN1; SMN2 3880/4885HIF1A 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.